CAS 51333-22-3

About the API

Systematic name (RS)-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
Trade name(s) Pulmicort (oral inhalation), Rhinocort (nasal spray), Entocort (oral)
Molecular Formula C25H34O6
Molecular Weight 430.53 g/mol
Physical properties white or almost-white crystalline powder
Therapeutic category Respiratory
Available formulations Inhalation Nasal Topical Oral Solid Oral Solid Long-Acting Suppositories
Regulations CEP Flag CEP Japan DMF Flag Japan DMF Other Flag Other US DMF Flag US DMF

General Information

General information about Budesonide

Budesonide belongs to a class of molecules termed glucocorticosteroids and is used for the treatment of Crohn’s disease, asthma, and allergic rhinitis. It exerts its effects by binding to the glucocorticoid receptor and suppressing inflammation caused by these conditions. In oral tablet form, budesonide decreases inflammation in the digestive tract as a result of Crohn’s disease, a painful condition marked by inflammation of the bowels. In oral inhalation form, this drug is prescribed to reduce inflammation and spasms in the lungs caused by asthma. Lastly, when administered as a nasal spray, budesonide is used to treat allergic rhinitis by reducing inflammation that is believed to cause symptoms such as wheezing, sneezing, and coughing.

 Budesonide: FDA

Budesonide became FDA approved in oral tablet form for the treatment of Crohn’s disease under the trade name Entocort in 2001, in oral inhalation form for the treatment of asthma under the trade name Pulmicort in 1997, and in nasal spray form for the treatment of allergic rhinitis under the trade name Rhinocort in 1994. It is currently manufactured through large-scale synthetic organic chemistry methods starting from simple, commercially available precursors.